Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula

被引:107
作者
Nishimura, Y
Suzuki, M
Nakamatsu, K
Kanamori, S
Yagyu, Y
Shigeoka, H
机构
[1] Kinki Univ, Sch Med, Dept Radiol, Osaka 5898511, Japan
[2] Kinki Univ, Sch Med, Dept Surg 1, Osaka 5898511, Japan
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2002年 / 53卷 / 01期
关键词
esophageal cancer; chemoradiation; T4; tumors; esophageal fistula;
D O I
10.1016/S0360-3016(01)02813-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: A prospective trial of concurrent chemoradiotherapy (CT-RT) with a protracted infusion of 5-fluorouracil and cisplatin was performed to evaluate the safety and efficacy of this protocol for T4 esophageal cancer (UICC 1997). Methods and Materials: Between 1998 and 2000, 28 patients with T4 esophageal squamous cell carcinomas were treated with concurrent CT-RT. Of the 28 patients, 15 had Stage III, 5 Stage IVA, and 8 Stage IV disease. Five of the T4 tumors had evidence of fistula before treatment. Patients received a protracted infusion of 5-fluorouracil 300 mg/m(2)/24 h on Days 1-14, a 1-h infusion of cisplatin 10 mg/body on Days 1-5 and 8-12, and concurrent radiation at a dose of 30 Gy in 15 fractions during 3 weeks. This schedule was repeated twice, with a 1-week split, for a total RT dose of 60 Gy during 7 weeks for 25 patients. For the remaining 3 patients, 30 Gy of preoperative CT-RT was administered. Results: Of the 25 patients who were treated with the full dose of CT-RT, 14 (56%) completed the two courses of-the CT-RT protocol, and 8 patients (32%) received the full dose of RT but a reduced dose of chemotherapy. Eight (32%) of the 25 tumors showed complete regression. Although Grade 3 hematologic toxicities were frequently noted, Grade 4 or more hematologic toxicities were few. Of the 5 T4 fistulous tumors, 2 demonstrated the disappearance of the fistula after CT-RT. However, the worsening or development of an esophageal fistula was noted in 5 patients. The 2-year survival rate for patients with Stage III was 2717,c, and the median survival time for those with Stage III and Stage IVA+IV was 12 and 5 months, respectively. Conclusion: Despite its significant toxicity for esophageal fistula, this concurrent CT-RT protocol of protracted 5-fluorouracil infusion and cisplatin appears feasible and effective for T4 esophageal cancer with or without fistulas. (C) 2002 Elsevier Science Inc.
引用
收藏
页码:134 / 139
页数:6
相关论文
共 17 条
[1]
Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study [J].
AlSarraf, M ;
Martz, K ;
Herskovic, A ;
Leichman, L ;
Brindle, JS ;
Vaitkevicius, VK ;
Cooper, J ;
Byhardt, R ;
Davis, L ;
Emami, B .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :277-284
[2]
Combined modality therapy for esophageal cancer [J].
Blanke, CD ;
Choy, H ;
Leach, SD .
SEMINARS IN RADIATION ONCOLOGY, 1997, 7 (03) :15-23
[3]
COMBINED-MODALITY THERAPY FOR ESOPHAGEAL-CARCINOMA - PRELIMINARY-RESULTS FROM A LARGE AUSTRALASIAN MULTICENTER STUDY [J].
BURMEISTER, BH ;
DENHAM, JW ;
OBRIEN, M ;
JAMIESON, GG ;
GILL, PG ;
DEVITT, P ;
YEOH, E ;
HAMILTON, CS ;
ACKLAND, SP ;
LAMB, DS ;
SPRY, NA ;
JOSEPH, DJ ;
ATKINSON, C ;
WALKER, QJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (04) :997-1006
[4]
HALVORSEN RA, 1989, RADIOL CLIN N AM, V27, P667
[5]
COMBINED CHEMOTHERAPY AND RADIOTHERAPY COMPARED WITH RADIOTHERAPY ALONE IN PATIENTS WITH CANCER OF THE ESOPHAGUS [J].
HERSKOVIC, A ;
MARTZ, K ;
ALSARRAF, M ;
LEICHMAN, L ;
BRINDLE, J ;
VAITKEVICIUS, V ;
COOPER, J ;
BYHARDT, R ;
DAVIS, L ;
EMAMI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (24) :1593-1598
[6]
Phase II study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus: Nine Japanese institutions trial [J].
Ishida, K ;
Iizuka, T ;
Ando, N ;
Ide, H .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1996, 26 (05) :310-315
[7]
Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: A preliminary analysis of the phase II intergroup trial 0122 [J].
Minsky, BD ;
Neuberg, D ;
Kelsen, DP ;
Pisansky, TM ;
Ginsberg, R ;
Benson, A .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :149-155
[8]
Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus [J].
Minsky, BD ;
Neuberg, D ;
Kelsen, DP ;
Pisansky, TM ;
Ginsberg, RJ ;
Pajak, T ;
Salter, M ;
Benson, AB .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (03) :517-523
[9]
MINSKY BD, 2000, P AN M AM SOC CLIN, V19, pA239
[10]
ESOPHAGEAL CANCER TREATED WITH RADIOTHERAPY - IMPACT OF TOTAL TREATMENT TIME AND FRACTIONATION [J].
NISHIMURA, Y ;
ONO, K ;
TSUTSUI, K ;
OYA, N ;
OKAJIMA, K ;
HIRAOKA, M ;
ABE, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 30 (05) :1099-1105